<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905589</url>
  </required_header>
  <id_info>
    <org_study_id>19.18.CLI</org_study_id>
    <nct_id>NCT04905589</nct_id>
  </id_info>
  <brief_title>Medium Chain Triglycerides (MCT) and Whey Protein Isolate (WPI) for Type 2 Diabetes Patients (Combine)</brief_title>
  <official_title>Effect of Combined Intake of Medium Chain Triglycerides (MCT) at Breakfast and Whey Protein Isolate (WPI) Preload at Lunch and Dinner on Diurnal Glucose and Satiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of effect on diurnal glycaemia following consumption of MCT and whey protein in&#xD;
      patients with type 2 diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study (Combine) is to evaluate the effects of Combined Intake of Medium&#xD;
      chain triglycerides (MCT) at breakfast and whey protein isolate (WPI) preload at lunch and&#xD;
      dinner for patients with type 2 diabetes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">July 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Open-label - randomization-concealed trial randomized in a 1:1:1 ratio</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diurnal glucose Incremental area under curve (iAUC) concentrations</measure>
    <time_frame>115 days</time_frame>
    <description>Constant glucose monitoring (CGM) comparing treatment regimen A-B-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose concentrations</measure>
    <time_frame>115 days</time_frame>
    <description>Mean, standard deviation and coefficient of variation of 24h glucose concentration as 24h 24h assessed by CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) glucose</measure>
    <time_frame>115 days</time_frame>
    <description>24h assessed by CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental area under curve (iAUC) glucose</measure>
    <time_frame>115 days</time_frame>
    <description>24h assessed by CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) questionnaire</measure>
    <time_frame>115 days</time_frame>
    <description>100-point VAS on satiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose mean</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Incremental area under curve (iAUC)</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin mean</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin Incremental area under curve (iAUC)</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric inhibitory polypeptide (GIP) - GLP-1 mean</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide-1 (GLP-1) mean</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric inhibitory polypeptide (GIP) - Incremental area under curve (iAUC)</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide-1 (GLP-1) Incremental area under curve (iAUC)</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide tyrosine tyrosine (PYY) mean</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide tyrosine tyrosine (PYY) Incremental area under curve (iAUC)</measure>
    <time_frame>115 days</time_frame>
    <description>Arterialised blood concentration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subsequent order of intake :&#xD;
Iso-voluminous water, breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subsequent order of intake :&#xD;
MCT in liquid form (75 ml of BetaQuik™), breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subsequent order of intake:&#xD;
MCT in liquid form (75 ml of BetaQuik™), breakfast, WPI in liquid from (12.5g of WheyBasics in 200ml water), lunch, WPI in liquid from (12.5g of WheyBasics in 200ml water)), dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BetaQuik™</intervention_name>
    <description>MCT (Medium chain triglycerides)</description>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>WheyBasics</intervention_name>
    <description>Whey Protein Isolate</description>
    <arm_group_label>ARM C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Iso-voluminous water</intervention_name>
    <description>Iso-voluminous Water as comparitor to Betaquik or WheyBasics</description>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, 25 to 65 years of age, inclusive.&#xD;
&#xD;
          2. Subjects with a BMI of ≤ 40kg/m2.&#xD;
&#xD;
          3. Established diagnosis of Type 2 diabetes mellitus (T2DM), documented by either HbA1c&#xD;
             6.5 -10.0% or active therapy with metformin at a daily dose of up to 3000 mg at&#xD;
             screening.&#xD;
&#xD;
          4. Willing and able to sign written informed consent prior to study entry.&#xD;
&#xD;
          5. Subjects with laboratory parameters within normal range, or showing no clinically&#xD;
             relevant deviations, as judged by the investigator.&#xD;
&#xD;
          6. Willing and able to comply with the requirements of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fasting blood glucose &gt;11mmol/L at screening.&#xD;
&#xD;
          2. Elevated liver transaminases &gt; 3 Upper limit of normal at screening.&#xD;
&#xD;
          3. Ongoing or recent (i.e. &lt; 3month) insulin therapy.&#xD;
&#xD;
          4. Ongoing or recent (i.e. &lt; 3month) GLP-1 therapy.&#xD;
&#xD;
          5. Ongoing or recent (i.e. &lt; 3month) treatment with any oral or injectable&#xD;
             glucose-lowering drug other than metformin.&#xD;
&#xD;
          6. Ongoing or recent weight loss interventions (e.g. dietary weight loss programmes) or&#xD;
             any history of bariatric surgery.&#xD;
&#xD;
          7. Ongoing treatment with anorectic drugs, steroids, medications known to affect gastric&#xD;
             motility, or any condition known to affect gastro-intestinal integrity and food&#xD;
             absorption.&#xD;
&#xD;
          8. Major medical/surgical event requiring hospitalization in the last 3 months.&#xD;
&#xD;
          9. Known allergy and intolerance to product components.&#xD;
&#xD;
         10. Alcohol intake higher than 4 units per day in line with National Health Service&#xD;
             guidelines.&#xD;
&#xD;
         11. History of regular smoking (daily or most days in a week) or use of nicotine products&#xD;
             (3 or more nicotine containing products).&#xD;
&#xD;
         12. Have a hierarchical link with the research team members.&#xD;
&#xD;
         13. Subjects who have been dosed in another clinical trial with any investigational&#xD;
             drug/new chemical entity within 3 months or 5 half-lives (whichever is longer) prior&#xD;
             to screening, or subjects currently participating in any investigational trial.&#xD;
&#xD;
         14. Positive pregnancy test at screening for women of child-bearing potential.&#xD;
&#xD;
         15. Subject who, in the judgment of the investigator, is likely to be noncompliant or&#xD;
             uncooperative during the study due to language barrier, poor mental development or any&#xD;
             other reason.&#xD;
&#xD;
         16. Subjects with fasting blood glucose that is not within 20% of the value at the&#xD;
             previous study visit. Note: In such cases, subjects can come in on another day within&#xD;
             the visit window at the discretion of the investigator, however, subjects will be&#xD;
             discontinued if the same observation is made at the new visit.&#xD;
&#xD;
         17. Evidence of eating disorders and regularly skipping breakfast and dinner.&#xD;
&#xD;
         18. Current or recent history (in last 3 months) of clinically significant&#xD;
             gastrointestinal, liver, cardiovascular, clotting, metabolic or endocrine disorders,&#xD;
             apart from T2DM, that in the opinion of the investigator might put the subject at risk&#xD;
             by entering the study or interfere with the aims of the study.&#xD;
&#xD;
         19. Total score of ≥ 20 on the Eating Attitude Test (EAT-26) at the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Kostas Tsintzas</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elham Pazirandeh Micol</last_name>
    <phone>+ 41 76 674 1360</phone>
    <email>elham.pazirandehmicol@nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Nottingham</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kostas Tsintzas</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

